In search of the optimal proteosome inhibitor. How, when and for whom?
作者信息
Engelhardt Monika, Bringhen Sara, Moreau Philippe, Wäsch Ralph, Waldschmidt Johannes
机构信息
University of Freiburg, Hematology and Oncology, Faculty of Freiburg, Hugstetterstr. 53, 79106 Freiburg.
Myeloma Unit, Division of Hematology, University of Turino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino.
出版信息
Haematologica. 2021 Oct 1;106(10):2539-2541. doi: 10.3324/haematol.2021.278838.
Abstract
摘要
相似文献
1
In search of the optimal proteosome inhibitor. How, when and for whom?
Haematologica. 2021 Oct 1;106(10):2539-2541. doi: 10.3324/haematol.2021.278838.
2
Use of proteasome inhibitors.
Curr Protoc Immunol. 2015 Apr 1;109:9.10.1-9.10.8. doi: 10.1002/0471142735.im0910s109.
3
Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo.
Blood. 2009 Apr 23;113(17):4027-37. doi: 10.1182/blood-2008-09-179796. Epub 2008 Dec 18.
4
Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades.
J Cell Physiol. 2009 Aug;220(2):450-9. doi: 10.1002/jcp.21787.
5
6
[Expression, purification of proteasome subunit PSMB1 and application in screening of possible proteasome inhibitors].
Sheng Wu Gong Cheng Xue Bao. 2012 Feb;28(2):233-42.
7
Search for Inhibitors of the Ubiquitin-Proteasome System from Natural Sources for Cancer Therapy.
Chem Pharm Bull (Tokyo). 2016;64(2):112-8. doi: 10.1248/cpb.c15-00768.
8
High-Resolution Snapshots of Proteasome Inhibitors in Action Revise Inhibition Paradigms and Inspire Next-Generation Inhibitor Design.
Chembiochem. 2016 Nov 17;17(22):2115-2117. doi: 10.1002/cbic.201600488. Epub 2016 Oct 11.
9
GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia.
Leukemia. 2011 Jul;25(7):1135-46. doi: 10.1038/leu.2011.50. Epub 2011 Apr 15.
10
Recent advances in proteasome inhibitor-based cancer therapies.
Curr Cancer Drug Targets. 2014;14(6):505. doi: 10.2174/1568009614666140805163018.
本文引用的文献
1
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK).
Haematologica. 2021 Oct 1;106(10):2694-2706. doi: 10.3324/haematol.2021.278399.
2
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
PLoS Med. 2021 Jan 11;18(1):e1003454. doi: 10.1371/journal.pmed.1003454. eCollection 2021 Jan.
3
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Lancet Oncol. 2020 Oct;21(10):1317-1330. doi: 10.1016/S1470-2045(20)30452-6. Epub 2020 Aug 28.
4
Once-weekly (70 mg/m ) vs twice-weekly (56 mg/m ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials.
Cancer Med. 2020 May;9(9):2989-2996. doi: 10.1002/cam4.2945. Epub 2020 Feb 28.
5
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies.
Haematologica. 2021 Apr 1;106(4):1079-1085. doi: 10.3324/haematol.2019.243428.
6
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Blood. 2019 May 2;133(18):1953-1963. doi: 10.1182/blood-2018-09-874396. Epub 2019 Feb 28.
7
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.
Leukemia. 2018 Apr;32(4):979-985. doi: 10.1038/leu.2017.327. Epub 2017 Nov 16.
8
Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial.
Br J Haematol. 2017 Nov;179(4):586-597. doi: 10.1111/bjh.14920. Epub 2017 Sep 29.
9
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Lancet Oncol. 2017 Oct;18(10):1327-1337. doi: 10.1016/S1470-2045(17)30578-8. Epub 2017 Aug 23.
10
Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.
Leukemia. 2016 Apr;30(4):995-8. doi: 10.1038/leu.2015.225. Epub 2015 Aug 14.
Zotero 插件